Get started
Work

Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Year: 2021
Type: erratum
DOI: 10.1007/s10120-021-01248-8
Authors: Eric Van Cutsem, Mayur Amonkar, Charles S. Fuchs, Maria Alsina, Mustafa Özgüroğlu, Yung-Jue Bang, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Al B. Benson, Weijing Sun, Zev A. Wainberg, Josephine M. Norquist, Xinqun Chen, Chie-Schin Shih, Kohei Shitara
Institutions: Universitair Ziekenhuis Leuven, KU Leuven, Merck & Co., Inc., Rahway, NJ, USA (United States), Yale Cancer Center, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Istanbul University-Cerrahpaşa, Istanbul University, Seoul National University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Aichi Cancer Center, Aichi Cancer Center Hospital, Universität Hamburg, University Cancer Center Hamburg, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Kansas, University of California, Los Angeles, National Cancer Center Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3206161923
Cites:
Cited by:
Related to: 10